Oral vinorelbine in combination with cisplatin or carboplatin in adjuvant chemotherapy of non-small cell lung cancer: A prospective multicentre study of feasibility, tolerability and 3-year survival

KOLEK, V., I. GRYGÁRKOVÁ, J. CHALUPA, L. KOUBKOVÁ, J. ŠVECOVÁ, Jana SKŘIČKOVÁ, L. OSTŘÍŽKOVÁ and D. SIXTOVÁ. Oral vinorelbine in combination with cisplatin or carboplatin in adjuvant chemotherapy of non-small cell lung cancer: A prospective multicentre study of feasibility, tolerability and 3-year survival. Online. In 13th Central European Lung Cancer Conference. 2012. ISSN 0169-5002. Available from: https://dx.doi.org/10.1016/j.lungcan.2012.05.063. [citováno 2024-04-24]

Basic information

• Original name: Oral vinorelbine in combination with cisplatin or carboplatin in adjuvant chemotherapy of non-small cell lung cancer: A prospective multicentre study of feasibility, tolerability and 3-year survival
• Authors: KOLEK, V., I. GRYGÁRKOVÁ, J. CHALUPA, L. KOUBKOVÁ, J. ŠVECOVÁ, Jana SKŘIČKOVÁ, L. OSTŘÍŽKOVÁ and D. SIXTOVÁ
• Edition: 13th Central European Lung Cancer Conference, 2012.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: Ireland
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 3.392
• Organization unit: Faculty of Medicine
• ISSN: 0169-5002
• Doi: http://dx.doi.org/10.1016/j.lungcan.2012.05.063
• Keywords in English: lung cancer; erlotinib

Abstract

Adjuvant cisplatinum-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA of non small-cell lung cancer (NSCLC) after radical resection. Results in stage IB were not conclusive. Vinorelbine is a preferable associated drug in this indication and a randomized study proved the comparable effectiveness and tolerability of vinorelbine given both orally or intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine gives better comfort to patients.